Skip to main content
. 2020 Sep 18;18:356. doi: 10.1186/s12967-020-02530-6

Table 3.

WOMAC scores before administration of treatments and 3, 6 and 12 months afterwards

WOMAC Time PRGF BM-MSCs + PRGF
Pain Baseline 6.6 (2.9) 6.6 (4.4)
3 months 4.3 (3.3)** 4.6 (3.3)*
6 months 4.4 (3)** 4.3 ( 3.6)
12 months 4.5 (3.2)** 4.1 (3.6)
Improvement (%) 27.3 45.5
Stiffness Baseline 3 (1.6) 3.3 (2.1)
3 months 1.9 (1.4)** 2.3 (2.2)**
6 months 2.2 (1.6) 2 (1.9)*
12 months 2.1 (1.6)* 2.1 (1.9)
Improvement (%) 33.3 50
Physical function Baseline 22.3 (12.8) 23.5 (13.2)
3 months 15.5 (12.6)** 17.6 (12.6)*
6 months 16.3 (11.1)* 14.9 (11.8)*
12 months 15.5 (11.9)** 16.7 (11.6)*
Improvement (%) 24.4 28.6
Overall Baseline 31.9 (16.2) 33.4 (18.7)
3 months 21.7 (17.1)** 24.4 (17.4)*
6 months 23 (15)** 21.3 (16.6)*
12 months 22.3 (15.8)** 23.0 (16.6)#
Improvement (%) 23.4 37.3

At baseline, 3 months, 6 months and 12 months, data are presented as mean (SD). Intragroup comparisons between follow-up values and baseline values of WOMAC score: *p < 0.01; **p < 0.05, #p = 0.05. Improvement (%) is the median improvement in percentage between the basal value and 12 months